enGene (NASDAQ:ENGN) Raised to “Sell” at Wall Street Zen

enGene (NASDAQ:ENGN) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

ENGN has been the subject of several other research reports. UBS Group cut their price target on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Raymond James Financial lowered shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price objective on the stock. in a research report on Friday, May 8th. Guggenheim cut shares of enGene from a “buy” rating to a “neutral” rating in a research note on Thursday, May 7th. Leerink Partners cut shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 target price for the company. in a research note on Friday, May 8th. Finally, Oppenheimer downgraded shares of enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $11.05.

enGene Stock Performance

enGene stock opened at $1.70 on Friday. The stock has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $5.02. The stock has a market capitalization of $113.88 million, a P/E ratio of -0.78 and a beta of -0.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. enGene has a 52 week low of $1.40 and a 52 week high of $12.25.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. During the same period in the prior year, the business posted $0.51 earnings per share. Analysts expect that enGene will post -1.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Cresset Asset Management LLC acquired a new stake in shares of enGene during the second quarter worth $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the second quarter valued at about $38,000. Raymond James Financial Inc. increased its position in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the period. Jump Financial LLC bought a new position in enGene during the fourth quarter worth about $121,000. Finally, Millennium Management LLC increased its position in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after acquiring an additional 7,472 shares during the period. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.